Emerging Opportunity: Bluechip Bull Run
Here is the latest financial fact sheet of SUVEN PHARMACEUTICALS. For more details, see the SUVEN PHARMACEUTICALS quarterly results and SUVEN PHARMACEUTICALS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.3 |
No. of shares | m | 254.57 |
1 Week | % | 4.1 |
1 Month | % | 2.0 |
1 Year | % | 42.9 |
52 week H/L | Rs | 767.0/427.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SUVEN PHARMACEUTICALS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | 353 | 825 | 631 | 629 | |
Low | Rs | NA | 174 | 206 | 457 | 388 | |
Sales per share (Unadj.) | Rs | 0 | 65.5 | 39.7 | 51.9 | 52.7 | |
Earnings per share (Unadj.) | Rs | 0 | 24.9 | 14.2 | 17.8 | 16.2 | |
Diluted earnings per share | Rs | 0 | 12.5 | 14.2 | 17.8 | 16.2 | |
Cash flow per share (Unadj.) | Rs | 0 | 26.8 | 15.5 | 19.4 | 18.0 | |
Dividends per share (Unadj.) | Rs | 0 | 5.00 | 2.00 | 5.00 | 6.00 | |
Adj. dividends per share | Rs | 0.00 | 2.50 | 2.00 | 5.00 | 6.00 | |
Avg Dividend yield | % | 0 | 1.9 | 0.4 | 0.9 | 1.2 | |
Book value per share (Unadj.) | Rs | 0 | 66.4 | 46.4 | 60.0 | 68.2 | |
Adj. book value per share | Rs | 0 | 33.2 | 46.4 | 60.0 | 68.2 | |
Shares outstanding (eoy) | m | 0 | 127.28 | 254.57 | 254.57 | 254.57 | |
Price / Sales ratio | x | 0 | 4.0 | 13.0 | 10.5 | 9.7 | |
Avg P/E ratio | x | 0 | 10.6 | 36.2 | 30.5 | 31.5 | |
P/CF ratio (eoy) | x | 0 | 9.8 | 33.3 | 28.1 | 28.2 | |
Price / Book Value ratio | x | 0 | 4.0 | 11.1 | 9.1 | 7.5 | |
Dividend payout | % | 0 | 20.1 | 14.1 | 28.0 | 37.1 | |
Avg Mkt Cap | Rs m | 0 | 33,533 | 131,203 | 138,502 | 129,395 | |
Total wages/salary | Rs m | 296 | 651 | 762 | 1,005 | 1,105 |
SUVEN PHARMACEUTICALS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 3,778 | 8,338 | 10,097 | 13,202 | 13,403 | |
Other income | Rs m | 6 | 181 | 142 | 924 | 464 | |
Total revenues | Rs m | 3,784 | 8,519 | 10,240 | 14,126 | 13,867 | |
Gross profit | Rs m | 1,716 | 4,330 | 4,967 | 6,228 | 5,739 | |
Depreciation | Rs m | 115 | 235 | 316 | 391 | 477 | |
Interest | Rs m | 28 | 231 | 117 | 85 | 128 | |
Profit before tax | Rs m | 1,579 | 4,045 | 4,677 | 6,676 | 5,597 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 486 | 875 | 1,053 | 2,138 | 1,484 | |
Profit after tax | Rs m | 1,093 | 3,170 | 3,623 | 4,538 | 4,113 | |
Gross profit margin | % | 45.4 | 51.9 | 49.2 | 47.2 | 42.8 | |
Effective tax rate | % | 30.8 | 21.6 | 22.5 | 32.0 | 26.5 | |
Net profit margin | % | 28.9 | 38.0 | 35.9 | 34.4 | 30.7 |
SUVEN PHARMACEUTICALS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 4,228 | 5,111 | 6,665 | 12,652 | 11,554 | |
Current liabilities | Rs m | 1,907 | 3,198 | 3,215 | 3,475 | 3,031 | |
Net working cap to sales | % | 61.4 | 22.9 | 34.2 | 69.5 | 63.6 | |
Current ratio | x | 2.2 | 1.6 | 2.1 | 3.6 | 3.8 | |
Inventory Days | Days | 18 | 155 | 200 | 171 | 148 | |
Debtors Days | Days | 1,425 | 513 | 370 | 653 | 302 | |
Net fixed assets | Rs m | 3,933 | 7,812 | 9,097 | 7,017 | 9,547 | |
Share capital | Rs m | 0 | 127 | 255 | 255 | 255 | |
"Free" reserves | Rs m | 5,776 | 8,320 | 11,554 | 15,017 | 17,097 | |
Net worth | Rs m | 5,776 | 8,448 | 11,808 | 15,272 | 17,352 | |
Long term debt | Rs m | 0 | 913 | 356 | 284 | 46 | |
Total assets | Rs m | 8,161 | 12,923 | 15,762 | 19,668 | 21,101 | |
Interest coverage | x | 57.6 | 18.5 | 41.1 | 79.3 | 44.7 | |
Debt to equity ratio | x | 0 | 0.1 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | |
Return on assets | % | 13.7 | 26.3 | 23.7 | 23.5 | 20.1 | |
Return on equity | % | 18.9 | 37.5 | 30.7 | 29.7 | 23.7 | |
Return on capital | % | 27.8 | 45.7 | 39.4 | 43.5 | 32.9 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 1,481 | 9,902 | 14,447 | 14,672 | |
Fx outflow | Rs m | 0 | 8,987 | 1,369 | 1,695 | 1,848 | |
Net fx | Rs m | 0 | -7,506 | 8,533 | 12,752 | 12,824 |
SUVEN PHARMACEUTICALS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 504 | 4,069 | 3,825 | 3,300 | 4,509 | |
From Investments | Rs m | -655 | -4,134 | -3,114 | -1,361 | -1,948 | |
From Financial Activity | Rs m | 260 | 73 | -757 | -1,565 | -2,358 | |
Net Cashflow | Rs m | 109 | 8 | -45 | 374 | 202 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Annaswamy Vaidheesh | COMP SEC: K Hanumantha Rao | YEAR OF INC: 2018 | BSE CODE: 543064 | FV (Rs): 1 | DIV YIELD (%): 0.9 |
Read: SUVEN PHARMACEUTICALS 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare SUVEN PHARMACEUTICALS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.